Welcome to our dedicated page for ABBOTT LABORATORIES SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABBOTT LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABBOTT LABORATORIES's regulatory disclosures and financial reporting.
Abbott Laboratories executive Elizabeth C. Cushman reported two share dispositions. On March 2, she completed an open-market sale of 263 common shares at $115.58 per share, leaving her with 38,573 shares held directly.
On February 27, she disposed of 1,421 shares at $116.26 per share to cover tax obligations through a tax-withholding transaction, rather than a traditional sale. Both transactions involve Abbott common shares without par value and reflect routine insider activity by the company’s EVP, General Counsel and Secretary.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported a tax-related share disposition. On February 27, 2026, 7,441 common shares were surrendered at $116.26 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 71,172 common shares and indirectly held 366 shares through a Profit Sharing Trust as of that date.
Abbott Laboratories Senior Vice President Eric Shroff reported equity awards that increase his direct holdings. He received an option for 44,821 shares at an exercise price of $0.00 and a grant of 10,873 common shares, both characterized as awards or other acquisitions.
The 10,873-share grant is a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program with a three-year term and no more than one-third vesting in any year, tied to a minimum return on equity target. The 44,821-share employee stock option, also under the 2017 program, becomes exercisable in annual increments of 14,940 shares on February 24, 2027 and February 24, 2028, and 14,941 shares on February 24, 2029.
ABBOTT LABORATORIES executive Christopher J. Scoggins reported equity awards consisting of stock options and performance-based shares. He received an employee stock option for 76,273 common shares at an exercise price of $0.0000 per share, granted under the Abbott Laboratories 2017 Incentive Stock Program.
The option becomes exercisable in three annual increments of 25,424 shares on February 24, 2027, 25,424 shares on February 24, 2028, and 25,425 shares on February 24, 2029. He was also granted 18,502 common shares as a performance-based restricted stock award with a three-year term, with no more than one‑third vesting in any year upon Abbott reaching a minimum return on equity target, and the award allows shares to be withheld for taxes.